Stockscreener 앱 받기
0.8276
0.17%
-0.0014
시간 외 거래:
.80
-0.0276
-3.33%
Palisade Bio Inc 주식(PALI)의 최신 뉴스
Palisade Bio secures Canadian tax credit for drug study By Investing.com - Investing.com Nigeria
Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC) - The Manila Times
Palisade Bio secures Canadian tax credit for drug study - Investing.com India
Palisade Bio, Inc. Announces Receipt of Cash Proceeds from - GlobeNewswire
Canadian Government Backs This Promising Ulcerative Colitis TreatmentWhat's Behind the $1.39M Investment? - StockTitan
Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire
Autonomix Medical, Inc. Participates in the Virtual Investor 'Top 5 for '25” On-Demand Conference - The Manila Times
Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand - Big News Network
Inside Palisade Bio's Ambitious 2025 Roadmap: 5 Critical Growth Drivers Revealed - StockTitan
PALI stock plunges to 52-week low, touches $1.34 - MSN
PALI-2108 colon-activated prodrug prevents ulcerative colitis progression - BioWorld Online
PALI’s Q2 earnings predictions: What the experts say - US Post News
Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis - GlobeNewswire
Q4 Earnings Roundup: Children's Place (NASDAQ:PLCE) And The Rest Of The Apparel Retailer Segment - The Globe and Mail
Palisade Bio's UC Drug Outperforms Standard Treatments in Preclinical StudiesKey Data Unveiled - StockTitan
Pre-market Movers: PALI, KROS, AVGR, TRVI... - RTTNews
Reviewing Protara Therapeutics (NASDAQ:TARA) and Palisade Bio (NASDAQ:PALI) - Defense World
JPMorgan Chase & Co. Purchases Shares of 8,200 Palisade Bio, Inc. (NASDAQ:PALI) - Defense World
PALI stock touches 52-week low at $1.32 amid market challenges - Investing.com
PALI stock touches 52-week low at $1.32 amid market challenges By Investing.com - Investing.com South Africa
Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress - The Manila Times
Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress - GlobeNewswire
Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar - The Manila Times
Palisade Bio CEO to Present at Webull Healthcare Investment Webinar This January - StockTitan
Palisade Bio reports positive data for UC drug trial - MSN
Palisade Bio begins MAD cohorts of Phase Ia/b ulcerative colitis therapy trial - Yahoo! Voices
Palisade Bio reports positive data for UC drug trial By Investing.com - Investing.com Australia
Puma Samples 601.33 g/t Gold at its McKenzie Gold Project - The Manila Times
Palisade Bio Completes All Five SAD Cohorts and Advances to - GlobeNewswire
Palisade Bio's Ulcerative Colitis Drug PALI-2108 Shows Strong Safety Profile in Phase 1 Study - StockTitan
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Palisade Bio Awards Stock Options to New Employee Under Inducement Plan - StockTitan
Palisade Bio (NASDAQ:PALI) Trading Up 2.9% – Here’s What Happened - Defense World
Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board - Markets Insider
Dr. Brian Feagan Appointed to Palisade Bio Clinical Advisory Board - citybiz
Palisade Bio Strengthens Clinical Advisory Board with Leading Gastroenterology Expert for UC Drug Development - StockTitan
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
PALIPalisade Bio, Inc. Latest Stock News & Market Updates - StockTitan
AleAnna, Inc. Announces Completion of Business Combination between Swiftmerge Acquisition Corp. and AleAnna Energy, LLC - The Manila Times
Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules - GlobeNewswire
Palisade Bio Raises $5M in Public Offering to Advance Phase 1 Clinical Trial Pipeline - StockTitan
What's Going On With Palisade Bio Stock On Thursday? - Benzinga
Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules - The Manila Times
Palisade Bio Raises $5M in Public Offering to Advance Key Clinical Trial of PALI-2108 - StockTitan
Nasdaq Down 50 Points; US Initial Jobless Claims Rise - Benzinga
Why DBV Technologies Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket - Benzinga
PALI Stock Plummets to 52-Week Low at $2.13 Amid Market Struggles - Investing.com
Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects - GlobeNewswire
Palisade Bio Reports Promising Safety Data in Phase 1 Ulcerative Colitis Drug Trial | PALI Stock News - StockTitan
3.13%
1.23%
자본화:
|
볼륨(24시간):